ALLARITY THERAPEUTICS INC (ALLR)
US0167444019 - Common Stock
We assign a fundamental rating of 0 out of 10 to ALLR. ALLR was compared to 568 industry peers in the Biotechnology industry. Both the profitability and financial health of ALLR have multiple concerns. ALLR is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year ALLR has reported negative net income.
In the past year ALLR has reported a negative cash flow from operations.
ALLR had negative earnings in each of the past 5 years.
In the past 5 years ALLR always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -162.28%, ALLR is not doing good in the industry: 86.90% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -162.28% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-123.51%
ROA(5y)-87.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ALLR so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ALLR has more shares outstanding than it did 1 year ago.
ALLR has a better debt/assets ratio than last year.
2.2 Solvency
ALLR has an Altman-Z score of -17.09. This is a bad value and indicates that ALLR is not financially healthy and even has some risk of bankruptcy.
ALLR has a worse Altman-Z score (-17.09) than 84.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -17.09 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
ALLR has a Current Ratio of 0.13. This is a bad value and indicates that ALLR is not financially healthy enough and could expect problems in meeting its short term obligations.
ALLR's Current ratio of 0.13 is on the low side compared to the rest of the industry. ALLR is outperformed by 97.70% of its industry peers.
A Quick Ratio of 0.13 indicates that ALLR may have some problems paying its short term obligations.
With a Quick ratio value of 0.13, ALLR is not doing good in the industry: 97.70% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.13 | ||
| Quick Ratio | 0.13 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 99.71% over the past year.
EPS 1Y (TTM)99.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
ALLR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.92% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y99.94%
EPS Next 2Y41.41%
EPS Next 3Y25.98%
EPS Next 5Y18.92%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ALLR. In the last year negative earnings were reported.
Also next year ALLR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ALLR's earnings are expected to grow with 25.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.41%
EPS Next 3Y25.98%
5. Dividend
5.1 Amount
No dividends for ALLR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ALLARITY THERAPEUTICS INC
NASDAQ:ALLR (12/20/2024, 8:00:00 PM)
After market: 1.0097 +0.02 (+1.98%)0.9901
-0.04 (-3.87%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners1.2%
Inst Owner Change-88.92%
Ins Owners12.32%
Ins Owner Change48.48%
Market Cap4.39M
Analysts43.33
Price TargetN/A
Short Float %6%
Short Ratio0.6
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.85%
Min EPS beat(2)11.28%
Max EPS beat(2)62.42%
EPS beat(4)2
Avg EPS beat(4)-282.05%
Min EPS beat(4)-1133.29%
Max EPS beat(4)62.42%
EPS beat(8)5
Avg EPS beat(8)-136.82%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-2900%
EPS NQ rev (3m)-2900%
EPS NY rev (1m)0%
EPS NY rev (3m)-2900%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-933.21
EYN/A
EPS(NY)-47.86
Fwd EYN/A
FCF(TTM)-3.57
FCFYN/A
OCF(TTM)-3.57
OCFYN/A
SpS0
BVpS-1.46
TBVpS-3.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -162.28% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-123.51%
ROA(5y)-87.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.13 | ||
| Quick Ratio | 0.13 | ||
| Altman-Z | -17.09 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.43%
EPS Next Y99.94%
EPS Next 2Y41.41%
EPS Next 3Y25.98%
EPS Next 5Y18.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y2.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y15.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.37%
OCF growth 3YN/A
OCF growth 5YN/A